Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
WVE-N531 Phase 2 Results Expected
WVE-N531 • Duchenne Muscular Dystrophy
Target Indication
Duchenne Muscular Dystrophy
Clinical Trial
Last updated: 12/4/2025
WVE
Wave Life Sciences Ltd.
Alpha-1 Antitrypsin Deficiency
Huntington Disease